Celltrion Pharm (Korea) Buy Hold or Sell Recommendation

068760 Stock  KRW 59,800  1,300  2.13%   
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Celltrion Pharm is 'Strong Sell'. Macroaxis provides Celltrion Pharm buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding 068760 positions.
  
Check out Celltrion Pharm Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool.
In addition, we conduct extensive research on individual companies such as Celltrion and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Celltrion Pharm. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Execute Celltrion Pharm Buy or Sell Advice

The Celltrion recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Celltrion Pharm. Macroaxis does not own or have any residual interests in Celltrion Pharm or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Celltrion Pharm's advice using the current market data and latest reported fundamentals.

Time Horizon

Risk Tolerance

Execute Advice
Sell Celltrion PharmBuy Celltrion Pharm
Strong Sell

Market Performance

Very WeakDetails

Volatility

Very steadyDetails

Hype Condition

StaleDetails

Current Valuation

OvervaluedDetails

Odds Of Distress

LowDetails

Economic Sensitivity

Moves slightly opposite to the marketDetails

Analyst Consensus

Not AvailableDetails

Reporting Quality (M-Score)

InapplicableDetails
For the selected time horizon Celltrion Pharm has a Mean Deviation of 2.08, Standard Deviation of 2.94 and Variance of 8.62
Macroaxis provides advice on Celltrion Pharm to complement and cross-verify current analyst consensus on Celltrion Pharm. Our investment recommendation engine determines the company's potential to grow exclusively from the perspective of an investor's current risk tolerance and investing horizon. To make sure Celltrion Pharm is not overpriced, please confirm all Celltrion Pharm fundamentals, including its operating margin, shares outstanding, shares owned by institutions, as well as the relationship between the current valuation and shares owned by insiders .

Celltrion Pharm Trading Alerts and Improvement Suggestions

Celltrion Pharm generated a negative expected return over the last 90 days
About 58.0% of the company shares are owned by insiders or employees

Celltrion Pharm Returns Distribution Density

The distribution of Celltrion Pharm's historical returns is an attempt to chart the uncertainty of Celltrion Pharm's future price movements. The chart of the probability distribution of Celltrion Pharm daily returns describes the distribution of returns around its average expected value. We use Celltrion Pharm price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Celltrion Pharm returns is essential to provide solid investment advice for Celltrion Pharm.
Mean Return
-0.14
Value At Risk
-5.48
Potential Upside
4.59
Standard Deviation
2.94
   Return Density   
       Distribution  
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Celltrion Pharm historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.

Celltrion Pharm Greeks

Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Celltrion Pharm or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Celltrion Pharm's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Celltrion stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α
Alpha over Dow Jones
-0.14
β
Beta against Dow Jones-0.63
σ
Overall volatility
2.99
Ir
Information ratio -0.06

Celltrion Pharm Volatility Alert

Celltrion Pharm exhibits very low volatility with skewness of 0.84 and kurtosis of 2.39. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Celltrion Pharm's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Celltrion Pharm's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.

Celltrion Pharm Fundamentals Vs Peers

Comparing Celltrion Pharm's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Celltrion Pharm's direct or indirect competition across all of the common fundamentals between Celltrion Pharm and the related equities. This way, we can detect undervalued stocks with similar characteristics as Celltrion Pharm or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Celltrion Pharm's fundamental indicators could also be used in its relative valuation, which is a method of valuing Celltrion Pharm by comparing valuation metrics with those of similar companies.
    
 Better Than Average     
    
 Worse Than Average Compare Celltrion Pharm to competition
FundamentalsCelltrion PharmPeer Average
Return On Equity0.0891-0.31
Return On Asset0.0341-0.14
Profit Margin0.09 %(1.27) %
Operating Margin0.11 %(5.51) %
Current Valuation5.87 T16.62 B
Shares Outstanding34.05 M571.82 M
Shares Owned By Insiders57.79 %10.09 %
Shares Owned By Institutions6.75 %39.21 %
Price To Earning62.82 X28.72 X
Price To Sales8.22 X11.42 X
Revenue398.74 B9.43 B
Gross Profit72.93 B27.38 B
EBITDA42.8 B3.9 B
Net Income34.58 B570.98 M
Cash And Equivalents80.19 B2.7 B
Cash Per Share815.33 X5.01 X
Total Debt39.4 B5.32 B
Debt To Equity0.64 %48.70 %
Current Ratio1.25 X2.16 X
Book Value Per Share10,914 X1.93 K
Cash Flow From Operations93.15 B971.22 M
Target Price136000.0
Number Of Employees2918.84 K
Beta0.23-0.15
Market Capitalization2.1 T19.03 B
Total Asset637.88 B29.47 B
Retained Earnings30.6 B9.33 B
Working Capital58.94 B1.48 B
Current Asset144.21 B9.34 B
Current Liabilities85.27 B7.9 B
Z Score31.88.72
Net Asset637.88 B

Celltrion Pharm Market Momentum

Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Celltrion . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.

About Celltrion Pharm Buy or Sell Advice

When is the right time to buy or sell Celltrion Pharm? Buying financial instruments such as Celltrion Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.

Use Investing Ideas to Build Portfolios

In addition to having Celltrion Pharm in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Junk Bonds Funds Thematic Idea Now

Junk Bonds Funds
Junk Bonds Funds Theme
Funds or Etfs that invest most of their assets into speculative (junk) bonds or to other fixed income instruments with interest rates 3 to 4 percentage points above government issues. The Junk Bonds Funds theme has 38 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Junk Bonds Funds Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Celltrion Stock

Celltrion Pharm financial ratios help investors to determine whether Celltrion Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Celltrion with respect to the benefits of owning Celltrion Pharm security.